HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
UPC
Universe Pharmaceuticals Inc.
There isn't enough reported data to score UPC yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
UPC Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Strong |
UPC's balance sheet is currently strong, but its profitability is weak. There isn't enough data to rate its revenue and cash flow.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
UPC PE Valuation
UPC has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
UPC Forward outlook
There aren't enough analyst estimates for UPC to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
UPC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q1 2024 | -$3,054.00 | -$1,206.00 |
| Q3 2023 | -$1,020.00 | +$420.00 |
| Q3 2022 | -$1,440.00 | -167% |
UPC has the edge over HIMS in the latest year-over-year earnings comparison.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over UPC in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
UPC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2024 | $23M | +66% |
| Q1 2024 | $12.9M | -30% |
| Q3 2023 | $13.8M | -13% |
| Q1 2023 | $18.5M | -24% |
| Q3 2022 | $15.9M | -67% |
| Q3 2021 | $48M | +213% |
| Q3 2020 | $15.4M | -7.6% |
| Q1 2020 | $15.4M | +85% |
UPC's revenue is recovering but still below its 2021 peak: $23M last quarter, up 44% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2024 | -35% | +36 points |
| Q1 2024 | -14% | -25 points |
| Q3 2023 | -27% | -55 points |
| Q1 2023 | 0.8% | -33 points |
| Q3 2022 | -71% | -105 points |
| Q1 2022 | 11% | -18 points |
| Q3 2021 | 28% | -1 points |
| Q3 2020 | 34% | -0.2 points |
UPC's operating margin was −35% last quarter, up 36 points from the same quarter a year ago, near the bottom of its range since 2018.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
UPC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2024 | -$9.7M | -$6M |
| Q1 2024 | -$2.5M | -151% |
| Q3 2023 | -$3.7M | +$3.7M |
| Q1 2023 | $4.8M | -21% |
| Q3 2022 | -$7.5M | -$5M |
| Q3 2021 | -$2.5M | -182% |
| Q3 2020 | $3M | -54% |
| Q1 2020 | $3M | -7.6% |
UPC's free cash flow was −$11M over the past year, against −$874,723 the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over UPC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
UPC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +35 shares |
| 1 year | +0.6% | +35 shares |
UPC has 6,077 diluted shares, up 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2020 | — |
| Q1 2020 | — |
| Q3 2019 | — |
| Q1 2019 | — |
| Q3 2018 | — |
| Q1 2018 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
UPC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2021 | -0.3x | Net Cash |
UPC has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
UPC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.5 | Neutral |
| Stochastic | 1.6 | Oversold |
UPC's weekly RSI is 36 (neutral) and its Stochastic is 2 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
UPC PE vs Healthcare Sector
| Metric | UPC | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
UPC has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
UPC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.26 | 53% below |
| 20 week MA | $4.17 | 63% below |
| 50 week MA | $3.71 | 59% below |
| 100 week MA | $5.34 | 71% below |
| 200 week MA | $665.0 | 100% below |
UPC is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over UPC on returns for 2026, with the stronger performance.
UPC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $14,616.0 | $5,940.0 | -59% |
| 2022 | $5,940.0 | $5,796.0 | -2.4% |
| 2023 | $5,796.0 | $1,206.0 | -79% |
| 2024 | $1,206.0 | $24.9 | -98% |
| 2025 | $24.9 | $5.62 | -77% |
| 2026 YTD | $5.62 | $1.53 | -73% |
UPC has finished every year since 2021 lower, and it's down 73% so far in 2026.